Category - Developments

Developments

Axsome AXS-05 meets primary endpoint in Phase 2/3 Alzheimer’s disease trial

Axsome Therapeutics’ (NASDAQ:AXSM) AXS-05 met its primary endpoint in a Phase 2/3 trial, called ADVANCE-1, in patients with Alzheimer’s disease (AD)-related agitation. The trial assessed 366 AD patients who were...

April 27, 2020

Developments

Avadel Pharma Phase 3 narcolepsy trial meets three co-primary efficacy endpoints

Avadel Pharmaceuticals (NASDAQ:AVDL) reported positive topline data from its Phase 3 trial of FT218 for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. The Phase 3 study, called...

April 27, 2020

Developments

BioSig subsidiary submits merimepodib IND for Phase 2 COVID-19 trial

ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies (NASDAQ: BSGM), submitted an IND application to the FDA to conduct a Phase 2 clinical trial of merimepodib for the treatment of COVID-19. Merimepodib is a...

April 24, 2020

Developments

Mesoblast cell therapy posts 83% survival in COVID-19 ARDS patients

Mesoblast (NASDAQ:MESO; ASX:MSB) reported an 83% survival in 10-of-12, or 83%, of ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) treated during March-April 2020...

April 24, 2020

Developments

Kiniksa Pharma’s vixarelimab meets primary endpoint in Phase 2a prurigo nodularis trial

Kiniksa Pharmaceuticals’ (NASDAQ:KNSA) vixarelimab met its primary efficacy endpoint in Phase 2a trial in patients with prurigo nodularis. Prurigo nodularis is a skin disease that causes hard, itchy nodules to form on...

April 22, 2020

Developments

Charlotte’s Web donates $1-million (US) worth of CBD in memory of Charlotte Figi

Charlotte’s Web (TSX:CWEB; OTC:CWBHF) donated $1-million (US) worth of CBD product to individuals who rely on the company’s products and may be struggling financially as a result of the COVID-19 pandemic. The...

April 21, 2020

Developments

Bee Vectoring gets strong endorsement from Georgia blueberry growers

With Georgia’s blueberry blooming period now complete, growers in the region using Bee Vectoring Technologies’ (TSXV, CVE: BEE; OTCQB:BEVVF) crop protection system reported high fruit set and low fruit drop, both...

April 21, 2020

Developments

Karyopharm Therapeutics doses first COVID-19 patient in selinexor study

Karyopharm Therapeutics (NASDAQ:KPTI) dosed the first patient in a Phase 2 clinical study evaluating low-dose oral selinexor in hospitalized patients with severe COVID-19. Selinexor is designed to block XPO1, a...

April 20, 2020

Developments

CytoSorbents gets FDA breakthrough therapy designation for CytoSorb

The FDA granted breakthrough therapy designation to CytoSorbents‘ (NASDAQ:CTSO) CytoSorb blood purification technology for the removal of ticagrelor during emergency surgery. Ticagrelor is an antiplatelet drug...

April 20, 2020

Developments

Mustang Bio MB-107 gets EMA advanced therapy medicinal product classification

The European Medicines Agency granted Mustang Bio’s (NASDAQ:MBIO) MB-107 with advanced therapy medicinal product classification for the treatment of X-linked severe combined immunodeficiency. Patients with X-linked...

April 20, 2020

Category - Developments

Axsome AXS-05 meets primary endpoint in Phase 2/3 Alzheimer’s disease trial

Avadel Pharma Phase 3 narcolepsy trial meets three co-primary efficacy endpoints

BioSig subsidiary submits merimepodib IND for Phase 2 COVID-19 trial

Mesoblast cell therapy posts 83% survival in COVID-19 ARDS patients

Kiniksa Pharma’s vixarelimab meets primary endpoint in Phase 2a prurigo nodularis trial

Charlotte’s Web donates $1-million (US) worth of CBD in memory of Charlotte Figi

Bee Vectoring gets strong endorsement from Georgia blueberry growers

Karyopharm Therapeutics doses first COVID-19 patient in selinexor study

CytoSorbents gets FDA breakthrough therapy designation for CytoSorb

Mustang Bio MB-107 gets EMA advanced therapy medicinal product classification

General

More